192 related articles for article (PubMed ID: 23360922)
1. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.
Winter JM; Tang LH; Klimstra DS; Liu W; Linkov I; Brennan MF; DʼAngelica MI; DeMatteo RP; Fong Y; Jarnagin WR; Oʼreilly EM; Allen PJ
Ann Surg; 2013 Aug; 258(2):331-5. PubMed ID: 23360922
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer.
Pokataev I; Kudaibergenova A; Artemyeva A; Popova A; Rumyantsev A; Podluzhny D; Kudashkin N; Fedyanin M; Tryakin A; Tjulandin S
J Gastrointest Cancer; 2019 Sep; 50(3):478-484. PubMed ID: 29675723
[TBL] [Abstract][Full Text] [Related]
3. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
Yamada S; Fujii T; Shimoyama Y; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
Pancreas; 2015 May; 44(4):660-4. PubMed ID: 25760429
[TBL] [Abstract][Full Text] [Related]
4. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
6. Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer.
Boone BA; Sabbaghian S; Zenati M; Marsh JW; Moser AJ; Zureikat AH; Singhi AD; Zeh HJ; Krasinskas AM
J Surg Oncol; 2014 Aug; 110(2):171-5. PubMed ID: 24665063
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9.
Ono M; Ono Y; Nakamura T; Tsuchikawa T; Kuraya T; Kuwabara S; Nakanishi Y; Asano T; Matsui A; Tanaka K; Ebihara Y; Kurashima Y; Noji T; Murakami S; Shichinohe T; Mitsuhashi T; Omori Y; Furukawa T; Taniue K; Suzuki M; Sugitani A; Karasaki H; Mizukami Y; Hirano S
Ann Surg Oncol; 2022 Aug; 29(8):5007-5019. PubMed ID: 35399143
[TBL] [Abstract][Full Text] [Related]
8. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
9. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.
Herman JM; Jabbour SK; Lin SH; Deek MP; Hsu CC; Fishman EK; Kim S; Cameron JL; Chekmareva M; Laheru DA; Narang AK; Pawlik TM; Hruban RH; Wolfgang CL; Iacobuzio-Donahue CA
Pancreas; 2018 Feb; 47(2):208-212. PubMed ID: 29329157
[TBL] [Abstract][Full Text] [Related]
10. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.
Morales-Oyarvide V; Rubinson DA; Dunne RF; Kozak MM; Bui JL; Yuan C; Qian ZR; Babic A; Da Silva A; Nowak JA; Khalaf N; Brais LK; Welch MW; Zellers CL; Ng K; Chang DT; Miksad RA; Bullock AJ; Tseng JF; Swanson RS; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Hornick JL; Ogino S; Fuchs CS; Hezel AF; Koong AC; Wolpin BM
Br J Cancer; 2017 Dec; 117(12):1874-1882. PubMed ID: 28982112
[TBL] [Abstract][Full Text] [Related]
11. Lymph node involvement beyond peripancreatic region in pancreatic head cancers: when results belie expectations.
Golse N; Lebeau R; Lombard-Bohas C; Hervieu V; Ponchon T; Adham M
Pancreas; 2013 Mar; 42(2):239-48. PubMed ID: 23038054
[TBL] [Abstract][Full Text] [Related]
12. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
14. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome.
Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
[TBL] [Abstract][Full Text] [Related]
15. Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer.
Sugiura T; Uesaka K; Mihara K; Sasaki K; Kanemoto H; Mizuno T; Okamura Y
Surgery; 2013 Nov; 154(5):1078-86. PubMed ID: 23973112
[TBL] [Abstract][Full Text] [Related]
16. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.
Bachet JB; Maréchal R; Demetter P; Bonnetain F; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
Ann Oncol; 2012 Sep; 23(9):2327-2335. PubMed ID: 22377565
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.
Maire F; Hammel P; Terris B; Paye F; Scoazec JY; Cellier C; Barthet M; O'Toole D; Rufat P; Partensky C; Cuillerier E; Lévy P; Belghiti J; Ruszniewski P
Gut; 2002 Nov; 51(5):717-22. PubMed ID: 12377813
[TBL] [Abstract][Full Text] [Related]
18. Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer.
Kang CM; Hwang HK; Park J; Kim C; Cho SK; Yun M; Lee WJ
Medicine (Baltimore); 2016 Apr; 95(17):e3452. PubMed ID: 27124039
[TBL] [Abstract][Full Text] [Related]
19. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
[TBL] [Abstract][Full Text] [Related]
20. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
